Mr Lucas leads the Expanded Access division at Durbin, having dedicated 100% of his time over the last 10 years specifically focused on pre-approval and pre-commercialization medicines’ access programs.
Highly knowledgeable and passionate about his work, Mr Lucas benefits from having first-hand experience on both the sponsor and vendor side in developing sustainable and robust access solutions for some of the world’s most complex and high value therapies. He prides himself on guiding teams through the development of innovative global access solutions, using his experience-derived knowledge to mitigate potential risks, whilst identifying key opportunities for the asset.
In addition to a comprehensive private consulting background specifically focused on early and emerging access strategy, Mr Lucas was former lead for access program initiatives at Biogen, where he planned and operationalized access initiatives for pipeline therapies, including one of the world’s largest rare disease EAPs, for the treatment of Spinal Muscular Atrophy.  He has contributed to the development of over 50 international access programs, covering a wide range  of disease areas, from specialist oncology programs to rare and ultra-orphan indications.